Wall Street Zen Downgrades Longeveron (NASDAQ:LGVN) to Sell

Longeveron (NASDAQ:LGVN) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research report issued on Saturday.

A number of other research analysts also recently commented on the stock. HC Wainwright decreased their price objective on shares of Longeveron from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Monday, May 4th. Maxim Group cut shares of Longeveron from a “buy” rating to a “hold” rating in a report on Monday, May 11th. Finally, Weiss Ratings downgraded shares of Longeveron from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, July 9th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $5.50.

Longeveron Trading Up 1.4%

Shares of Longeveron stock opened at $0.62 on Friday. Longeveron has a 12-month low of $0.47 and a 12-month high of $1.80. The stock has a market cap of $19.38 million, a P/E ratio of -0.55 and a beta of -0.35. The company has a quick ratio of 3.88, a current ratio of 3.88 and a debt-to-equity ratio of 0.05. The business’s 50 day moving average is $0.74 and its 200-day moving average is $0.74.

Longeveron (NASDAQ:LGVN) last released its earnings results on Wednesday, May 13th. The company reported ($0.19) earnings per share for the quarter, meeting the consensus estimate of ($0.19). The business had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.33 million. Longeveron had a negative net margin of 1,844.49% and a negative return on equity of 202.41%. Equities research analysts predict that Longeveron will post -0.68 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Longeveron

A hedge fund recently bought a new stake in Longeveron stock. ADAR1 Capital Management LLC acquired a new stake in Longeveron Inc. (NASDAQ:LGVN) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 200,000 shares of the company’s stock, valued at approximately $208,000. ADAR1 Capital Management LLC owned 0.86% of Longeveron at the end of the most recent reporting period. Institutional investors and hedge funds own 10.01% of the company’s stock.

Longeveron Company Profile

Longeveron Inc is a clinical-stage biotechnology company focused on the development and commercialization of allogeneic cellular therapies designed to address aging-related and inflammatory conditions. The company’s primary therapeutic candidate, Lomecel-B, is an off-the-shelf mesenchymal stem cell product derived from bone marrow. Through its proprietary manufacturing process, Longeveron aims to produce a consistent, scalable cell therapy platform with potential applications in multiple disease areas.

Longeveron’s pipeline encompasses several ongoing and completed clinical studies.